Derivation and Validation of a Prediction Model for Venous Thromboembolism in Primary Care

BACKGROUND  Most episodes of venous thromboembolism (VTE) occurred in primary care. To date, no score potentially able to identify those patients who may deserve an antithrombotic prophylaxis has been developed. AIM  The objective of this study is to develop and validate a prediction model for VTE in primary care. METHODS  Using the Health Search Database, we identified a cohort of 1,359,880 adult patients between 2002 and 2013. The date of the first General Practitioner's (GP) visit was the cohort entry date. All VTE cases (index date) observed up to December 2014 were identified. The cohort was randomly divided in a development and a validation cohort. According to nested case-cohort analysis, up to five controls were matched to their respective cases on month and year of cohort entry and duration of follow-up.The score was evaluated according to explained variance (pseudo R2) as a performance measure, ratio of predicted to observed cases as model calibration and area under the curve (AUC) as discrimination measure. RESULTS  The score was able to explain 27.9% of the variation for VTE occurrence. The calibration measure revealed a margin of error lower than 10% in 70% of the population. In terms of discrimination, AUC was 0.82 (95% confidence interval: 0.82-0.83). Results of sensitivity analyses substantially confirmed these findings. CONCLUSION  The present score demonstrated a very good accuracy in predicting the risk of VTE in primary care. This score may be therefore implemented in clinical practice so aiding GPs in making decision on patients potentially at risk of VTE.

[1]  Ben Van Calster,et al.  Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators. , 2018, European urology.

[2]  Agus Salim,et al.  Comparisons of risk prediction methods using nested case‐control data , 2017, Statistics in medicine.

[3]  F. Dentali,et al.  Efficacy and safety of extended thromboprophylaxis for medically ill patients , 2017, Thrombosis and Haemostasis.

[4]  F. Dentali,et al.  Efficacy and safety of extended antithrombotic prophylaxis in elderly medically ill patients , 2017, European Respiratory Journal.

[5]  Kathleen F. Kerr,et al.  Assessing the Clinical Impact of Risk Prediction Models With Decision Curves: Guidance for Correct Interpretation and Appropriate Use. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Yvonne Vergouwe,et al.  A calibration hierarchy for risk models was defined: from utopia to empirical data. , 2016, Journal of clinical epidemiology.

[7]  B. Wiens,et al.  Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. , 2016, The New England journal of medicine.

[8]  Ewout W Steyerberg,et al.  Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests , 2016, British Medical Journal.

[9]  Sabine Van Huffel,et al.  A spline-based tool to assess and visualize the calibration of multiclass risk predictions , 2015, J. Biomed. Informatics.

[10]  Benjamin R Saville,et al.  Decision curve analysis. , 2015, JAMA.

[11]  J. Gurwitz,et al.  Venous thromboembolism in older adults: A community-based study. , 2014, The American journal of medicine.

[12]  D. Aujesky,et al.  Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism , 2013, Thrombosis and Haemostasis.

[13]  M. Schumacher,et al.  Nested case-control studies in cohorts with competing events. , 2014, Epidemiology.

[14]  Scott Boyer,et al.  Drug-Induced Acute Myocardial Infarction: Identifying ‘Prime Suspects’ from Electronic Healthcare Records-Based Surveillance System , 2013, PloS one.

[15]  G. Trifirò,et al.  Burden of community-acquired pneumonia in Italian general practice , 2013, European Respiratory Journal.

[16]  P. Royston,et al.  External validation of a Cox prognostic model: principles and methods , 2013, BMC Medical Research Methodology.

[17]  S. Goldhaber.  Venous thromboembolism: epidemiology and magnitude of the problem. , 2012, Best practice & research. Clinical haematology.

[18]  S. Goodman,et al.  Beyond the Usual Prediction Accuracy Metrics: Reporting Results for Clinical Decision Making , 2012, Annals of Internal Medicine.

[19]  Patrik Magnusson,et al.  American Journal of Epidemiology Practice of Epidemiology Risk Prediction Measures for Case-cohort and Nested Case-control Designs: an Application to Cardiovascular Disease , 2022 .

[20]  Michael K Gould,et al.  Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[21]  G. Mazzaglia,et al.  Assessing 5-year incidence rates and determinants of osteoporotic fractures in primary care. , 2012, Bone.

[22]  Timothy J Wilt,et al.  Venous Thromboembolism Prophylaxis in Hospitalized Medical Patients and Those With Stroke: A Background Review for an American College of Physicians Clinical Practice Guideline , 2011, Annals of Internal Medicine.

[23]  A. Turpie,et al.  Predictive and associative models to identify hospitalized medical patients at risk for VTE. , 2011, Chest.

[24]  Valentin Rousson,et al.  Decision curve analysis revisited: overall net benefit, relationships to ROC curve analysis, and application to case-control studies , 2011, BMC Medical Informatics Decis. Mak..

[25]  C. Cimminiello,et al.  Venous thromboembolism in medical patients treated in the setting of primary care: a nationwide case-control study in Italy. , 2010, Thrombosis research.

[26]  P. Prandoni,et al.  A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score , 2010, Journal of thrombosis and haemostasis : JTH.

[27]  N. Obuchowski,et al.  Assessing the Performance of Prediction Models: A Framework for Traditional and Novel Measures , 2010, Epidemiology.

[28]  W. Ageno,et al.  In-hospital symptomatic venous thromboembolism and antithrombotic prophylaxis in Internal Medicine , 2009, Thrombosis and Haemostasis.

[29]  M. Crowther,et al.  Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. , 2008, Blood.

[30]  R. Goldberg,et al.  Venous thromboembolism in the outpatient setting. , 2007, Archives of internal medicine.

[31]  J. Douketis,et al.  Meta-analysis: Anticoagulant Prophylaxis to Prevent Symptomatic Venous Thromboembolism in Hospitalized Medical Patients , 2007, Annals of Internal Medicine.

[32]  Iztok Hozo,et al.  When Should Potentially False Research Findings Be Considered Acceptable? , 2007, PLoS medicine.

[33]  E. Elkin,et al.  Decision Curve Analysis: A Novel Method for Evaluating Prediction Models , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[34]  J. Bosson,et al.  A prospective observational study of a cohort of outpatients with an acute medical event and reduced mobility: incidence of symptomatic thromboembolism and description of thromboprophylaxis practices , 2006, Journal of internal medicine.

[35]  M. Prins,et al.  Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial , 2006, BMJ : British Medical Journal.

[36]  G. Mazzaglia,et al.  Computerized general practice databases provide quick and cost-effective information on the prevalence of angina pectoris. , 2005, Italian heart journal : official journal of the Italian Federation of Cardiology.

[37]  S. Goldhaber,et al.  Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients , 2004, Circulation.

[38]  J. Ray.  Dyslipidemia, statins, and venous thromboembolism: a potential risk factor and a potential treatment , 2003, Current opinion in pulmonary medicine.

[39]  J. Caprini,et al.  Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. , 2001, Seminars in hematology.

[40]  M. Samama,et al.  An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. , 2000, Archives of internal medicine.

[41]  A. Turpie,et al.  A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. , 1999, The New England journal of medicine.

[42]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[43]  D. Hosmer,et al.  A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. , 1991, Archives of internal medicine.

[44]  D. Cox.  Note on Grouping , 1957 .